Key Points
- On Dec. 16 CEO Christopher Richard Anzalone sold 54,298 shares at an average $62.58 for about $3.40M (he also sold 130,000 shares on Dec. 15 at $68.85 for ~$8.95M), leaving him with 3,916,957 shares — a 1.37% ownership decrease.
- Shares were down about 5.5% on the report; Arrowhead (ARWR) has a market cap of $8.79B and a 1‑year trading range of $9.57 to $72.36 with 50/200‑day moving averages of $46.66/$30.26.
- Analysts remain generally positive with a consensus rating of “Moderate Buy” and an average price target of $58.56, while several firms recently raised targets (e.g., BofA to $81, HC Wainwright to $85).
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 54,298 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $62.58, for a total transaction of $3,397,968.84. Following the sale, the chief executive officer owned 3,916,957 shares of the company's stock, valued at approximately $245,123,169.06. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Christopher Richard Anzalone also recently made the following trade(s):
- On Monday, December 15th, Christopher Richard Anzalone sold 130,000 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $68.85, for a total transaction of $8,950,500.00.
Arrowhead Pharmaceuticals Stock Down 5.5%
Shares of NASDAQ ARWR opened at $64.66 on Wednesday. The firm has a market cap of $8.79 billion, a P/E ratio of -808.15 and a beta of 1.28. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $9.57 and a 1 year high of $72.36. The firm's 50 day moving average price is $46.66 and its 200 day moving average price is $30.26.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently commented on ARWR shares. Morgan Stanley lifted their price objective on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an "equal weight" rating in a research report on Wednesday, November 26th. Bank of America lifted their price target on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a "buy" rating in a report on Tuesday, December 9th. Piper Sandler upped their price objective on shares of Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an "overweight" rating in a research note on Wednesday, November 19th. HC Wainwright raised their target price on shares of Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the stock a "buy" rating in a research report on Tuesday, December 2nd. Finally, Chardan Capital reiterated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday, December 1st. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $58.56.
Read Our Latest Report on Arrowhead Pharmaceuticals
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 138.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock valued at $60,962,000 after acquiring an additional 2,774,933 shares in the last quarter. Marshall Wace LLP lifted its stake in shares of Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company's stock worth $34,065,000 after purchasing an additional 2,096,238 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of Arrowhead Pharmaceuticals by 3,142.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company's stock worth $71,797,000 after buying an additional 2,017,489 shares during the period. Norges Bank purchased a new stake in shares of Arrowhead Pharmaceuticals in the second quarter worth about $30,414,000. Finally, Vanguard Group Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 8.4% in the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company's stock valued at $168,201,000 after buying an additional 1,018,273 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.
About Arrowhead Pharmaceuticals
(
Get Free Report)
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
